About: Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials
Creator	Arab-Zozani, Morteza Ghoddoosi-Nejad, Djavad Hassanipour, Soheil
Source	Medline; PMC
abstract	INTRODUCTION: An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the WHO on 11 March 2020. Due to the unknown nature of the disease and the lack of specific drugs, several potential treatments were used for patients. This systematic review and meta-analysis will evaluate studies of the effects of favipiravir in COVID-19 pneumonia. METHODS AND ANALYSIS: We will search electronic databases including LitCovid hub, PubMed, Scopus, ISI Web of Sciences, Cochrane and Embase using keywords related to COVID-19 and favipiravir. We will search the reference lists of all included studies and reviews. We will also search for clinical trial registries, such as ClinicalTrials.gov, for the ongoing clinical trials. All randomised clinical trials investigating the safety and efficacy of favipiravir compared with other control groups for the treatment of patients with confirmed infection with SARS-CoV-2 will be included. Patients’ survival at the end of the treatment as well as the follow-up will be the primary outcome of the treatment, followed by the time and rate of the patient with a negative COVID-19 test. The desired secondary outcome will consist of a decreased rate of symptoms, proportion of intensive care unit (ICU) transfers, length of the hospital stay, ICU treatments, the quality of life and additional adverse events. Data synthesis will be conducted using CMA V.2. Two independent investigators will be screening titles, abstracts and full texts of included studies, based on eligibility criteria. These investigators will then independently extract the data and appraise the quality of said studies. All potential discrepancies will be resolved through consultation with the third reviewer. Statistical heterogeneity will be assessed using a standard I(2) test. A funnel plot, Egger’s test and Begg’s test will be used for detecting asymmetry to explore possible publication bias. ETHICS AND DISSEMINATION: All findings of this systematic review and meta-analysis will help identify the safety and efficacy of favipiravir for patients with COVID-19. Given that the design of the study is a systematic review, there is no need to follow the code of ethics protocol. The results of this study will be published in a reputable journal. PROSPERO REGISTRATION NUMBER: CRD42020180032.
has issue date	2020-07-31(xsd:dateTime)
bibo:doi	10.1136/bmjopen-2020-039730
bibo:pmid	32737100
has license	cc-by-nc
sha1sum (hex)	d366d9447bff0416828a2381a5bb10af8f5f4135
schema:url	https://doi.org/10.1136/bmjopen-2020-039730
resource representing a document's title	Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials
has PubMed Central identifier	PMC7397976
has PubMed identifier	32737100
schema:publication	BMJ Open
resource representing a document's body	covid:d366d9447bff0416828a2381a5bb10af8f5f4135#body_text
is schema:about of	named entity 'subgroup analyses' named entity 'nucleic acid analogue' named entity 'MAZ' named entity 'purine' named entity 'MAZ' named entity 'Open access' named entity 'Open access' named entity 'Embase' named entity 'empirical evidence' named entity 'data extraction' named entity 'favipiravir' named entity 'COVID' named entity 'favipiravir' named entity 'clinical trial registries' named entity 'ethical approval' named entity 'systematic review' named entity 'Farsi' named entity 'remdesivir' named entity 'coronavirus' named entity 'Medical Subject Headings' named entity 'random effects model' named entity 'chronic respiratory disease' named entity 'reporting bias' named entity 'Avigan' named entity 'Favipiravir' named entity 'Favipiravir' named entity 'Japan' named entity 'treatment of patients' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'chloroquine phosphate' named entity 'WHO' named entity 'influenza A virus' named entity 'SARS-CoV' named entity 'Favipiravir' named entity 'favipiravir' named entity 'cough' named entity 'follow-up' named entity 'China' named entity 'RNA-dependent RNA polymerase' named entity 'data extraction' named entity 'Mantel-Haenszel' named entity 'Scientific Information Database' named entity 'PROSPERO' named entity 'coronavirus' named entity 'infection' named entity 'Scopus' named entity 'ICU' named entity 'COVID-19' named entity 'follow-up' named entity 'RdRp' named entity 'DGN' named entity 'DGN' named entity 'COVID' named entity 'chloroquine' named entity 'WHO' named entity 'DGN' named entity 'coronavirus' named entity 'fever' named entity 'Iran' named entity 'clinical trials' named entity 'COVID' named entity 'global health emergency' named entity 'COVID' named entity 'chronic health conditions' named entity 'SARS CoV' named entity 'Wuhan' named entity 'Arbidol' named entity 'antiviral medication' named entity 'ISI' named entity 'Pharmaceuticals and Medical Devices Agency' named entity '11 March 2020' named entity 'follow-up' named entity 'favipiravir' named entity 'Patient consent' named entity 'clinical studies' named entity 'treatment of patients' named entity 'coronavirus 2019' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software